Long-and short-acting beta 2-adrenergic agonists. Effects on airway function in patients with asthma

Inhaled beta-adrenergic agonist bronchodilators are integral components of effective asthma treatment. However, the risk of asthma morbidity and mortality associated with the regular use of certain inhaled beta-agonists was first noted in the United Kingdom during the 1960s and in New Zealand during the 1970s. There are also concerns that long-term use of both long-acting and short-acting inhaled beta-agonists may cause a loss of asthma control in some patients. These experiences have caused some investigators to question the safety of inhaled beta-agonists in patients with asthma. This review attempts to address these issues, which are of concern to both physicians and patients alike, and aims to increase the clinician's understanding and awareness of the problems and treatment options.